The Phospho-CD40 (Thr254) Antibody (Catalog: AF3693) is a rabbit polyclonal antibody developed by Affinity Biosciences. Key features include:
| Property | Detail |
|---|---|
| Target | Phosphorylated CD40 at Thr254 |
| Application | Western blot (WB) |
| Reactivity | Human, Mouse |
| Molecular Weight | 31 kDa (calculated) |
| UniProt ID | P25942 |
| RRID | AB_2847007 |
| Epitope Specificity | Recognizes CD40 phosphorylated at Thr254, validated via peptide ELISA |
This antibody is critical for distinguishing activated CD40 from its unphosphorylated form, providing insights into CD40-mediated signaling pathways .
CD40 engagement by its ligand (CD40L) triggers recruitment of TRAF adaptor proteins (e.g., TRAF2, TRAF6), activating NF-κB, MAPK, and PI3K pathways . Phosphorylation at Thr254 is implicated in regulating these interactions:
Structural role: CD40’s cytoplasmic domain contains TRAF-binding motifs. Phosphorylation at Thr254 may alter conformational accessibility for TRAF proteins .
Functional impact: CD40 phosphorylation modulates downstream events such as B cell proliferation, antibody class switching, and dendritic cell maturation .
The Phospho-CD40 (Thr254) Antibody facilitates:
Mechanistic studies: Tracking CD40 activation in autoimmune diseases (e.g., lupus, rheumatoid arthritis) where CD40 signaling is dysregulated .
Therapeutic development: Evaluating CD40 antagonists (e.g., ABBV-323) that block CD40L binding or phosphorylation-dependent signaling .
Immune profiling: Detecting activated CD40 in tumor microenvironments or inflammatory tissues .
Specificity validation: Further studies are needed to confirm Thr254’s role in TRAF binding versus other phosphosites (e.g., Ser272) .
Functional assays: Link phosphorylation status to CD40 oligomerization (antiparallel vs. signaling-competent dimers) .
Therapeutic targeting: Explore whether anti-CD40 mAbs (e.g., ABBV-323) interfere with phosphorylation-dependent signaling .